Related Experiment Videos
Clinical cancer proteomics: promises and pitfalls
Ayodele Alaiya1, Mai Al-Mohanna, Stig Linder
1Department of Biological and Medical Research, King Faisal Specialist Hospital and Research Center, P.O. Box 3354 Riyadh 11211 (MBC#03), Saudi Arabia. AAlaiya@Kfshrc.edu.sa
Journal of Proteome Research
|August 9, 2005
Summary
Proteomics can identify cancer biomarkers in tissues and serum. Validation using techniques like immunohistochemistry is crucial due to challenges in sample representativity and sensitivity.
Area of Science:
- Biochemistry
- Oncology
- Proteomics
Background:
- Proteome analysis offers potential for identifying cancer biomarkers in tissues and serum.
- It enables the study of protein expression profiles and signaling pathway activity.
- Challenges include tumor representativity, sample contamination, and low biomarker concentrations in serum.
Purpose of the Study:
- To review recent advances in proteomic analysis of human tumors.
- To highlight the importance of validating proteomic findings.
- To discuss the application of proteomics in biomarker discovery and diagnosis.
Main Methods:
- Review of published proteomic studies on human tumors and serum.
- Discussion of techniques for protein separation and analysis.
- Emphasis on validation methods like immunohistochemistry.
Main Results:
- Proteomics can identify potential biomarkers and protein expression profiles.
- Low concentrations of tumor proteins in serum necessitate prefractionation.
- Artificial learning methods can enhance diagnostic capabilities.
Conclusions:
- Proteomic analysis is a promising approach for biomarker identification and cancer diagnosis.
- Validation of identified biomarkers in representative tumor materials is essential.
- Despite challenges, proteomics holds significant potential for advancing oncology.